Evaluation and survey of malaria chemoprevention drug resistance in infant from Koutiala, Mali

Monitoring and evaluation of molecular markers drug resistance during seasonal malaria chemoprevention with sulfadoxine-pyrimethamine and amodiaquine implementation in Koutiala, Mali

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202401827533382

Enrollment

1000

Registered

2024-01-12

Start date

2022-01-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria

Interventions

NonSMC

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: i. Child who received SP or AQ in the previous month; ii. Child suffering from malaria diagnosed or under treatment at the time of implementation; iii. Child with a known allergy to SP or AQ; iv. adults never have taken SMC

Exclusion criteria

Exclusion criteria: 1. Known allergy to SMC medicine 2. Child with severe malaria 3. Child on cotrimoxazole

Design outcomes

Primary

Measure	Time frame
Measuring molecular markers of SP+AQ resistance will provide evidence for the spread of drug-resistant parasites SMC implementation.	—

Secondary

Measure	Time frame
In addition, measuring the incidence of malaria morbidity and mortality may correspond to a decline in SMC effectiveness over the past ten years.	—

Countries

Mali

Contacts

Public ContactSamba Sow

Directeur

ssow@cvd-mali.org+22376348947

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026